New data suggest that Donanemab, an investigational therapeutic , has the potential to slow the development of mild cognitive decline. This therapy focuses on clearing beta-amyloid within the https://umarkpbq321025.aboutyoublog.com/51939165/donanemab-an-potential-innovative-cognitive-approach